Literature DB >> 30705846

DARPP-32 and t-DARPP isoform in non-small cell lung cancer (NSCLC): could they drive patients' clinical management and be a therapeutic target?

Giuseppe Lamberti1,2, Chiara Peterle1,2, Francesco Gelsomino1.   

Abstract

Entities:  

Year:  2018        PMID： 30705846      PMCID： PMC6328690          DOI： 10.21037/tlcr.2018.12.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

1.  Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.

Authors:  Abbes Belkhiri; Altaf A Dar; Dun Fa Peng; Mohammad H Razvi; Cammie Rinehart; Carlos L Arteaga; Wael El-Rifai
Journal:  Clin Cancer Res       Date:  2008-06-25       Impact factor: 12.531

2.  Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.

Authors:  Jun Hong; Ahmed Katsha; Pengcheng Lu; Yu Shyr; Abbes Belkhiri; Wael El-Rifai
Journal:  Cancer Res       Date:  2012-06-28       Impact factor: 12.701

3.  DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.

Authors:  Shoumin Zhu; Abbes Belkhiri; Wael El-Rifai
Journal:  Gastroenterology       Date:  2011-07-07       Impact factor: 22.682

4.  High Expression of DARPP-32 in Colorectal Cancer Is Associated With Liver Metastases and Predicts Survival for Dukes A and B Patients: Results of a Pilot Study.

Authors:  Mario Kopljar; Leonardo Patrlj; Dragan Korolija-Marinic; Matija Horzic; Kristijan Cupurdija; Bore Bakota
Journal:  Int Surg       Date:  2015-02

5.  Overexpression of DARPP-32 in colorectal adenocarcinoma.

Authors:  M S J Wang; Y Pan; N Liu; C Guo; L Hong; D Fan
Journal:  Int J Clin Pract       Date:  2005-01       Impact factor: 2.503

6.  Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP.

Authors:  Wa'el El-Rifai; Michael F Smith; Guolian Li; Andy Beckler; Virginia S Carl; Elizabeth Montgomery; Sakari Knuutila; Christopher A Moskaluk; Henry F Frierson; Steven M Powell
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.

Authors:  Long Gu; Sarah Waliany; Susan E Kane
Journal:  PLoS One       Date:  2009-07-13       Impact factor: 3.240

8.  Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.

Authors:  Luke H Hoeppner; Ying Wang; Anil Sharma; Naureen Javeed; Virginia P Van Keulen; Enfeng Wang; Ping Yang; Anja C Roden; Tobias Peikert; Julian R Molina; Debabrata Mukhopadhyay
Journal:  Mol Oncol       Date:  2014-08-30       Impact factor: 6.603

9.  Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.

Authors:  Sophie Hamel; Amélie Bouchard; Cristiano Ferrario; Saima Hassan; Adriana Aguilar-Mahecha; Marguerite Buchanan; Louise Quenneville; Wilson Miller; Mark Basik
Journal:  Breast Cancer Res Treat       Date:  2009-03-20       Impact factor: 4.872

10.  Darpp-32 and t-Darpp are differentially expressed in normal and malignant mouse mammary tissue.

Authors:  Jessica L Christenson; Susan E Kane
Journal:  Mol Cancer       Date:  2014-08-15       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.